APP and Alzheimer disease: Inhibition of HDAC2, conversely, slows down AD progression through ameliorating amyloid beta-induced neuronal impairments in APP/PS1 mice [59], enhancing mitochondrial respiration and reducing the levels of neurotoxic amyloid beta peptides in induced pluripotent stem cell-derived neurons [60].